Research Topics
Species | Daniele LaszloSummaryAffiliation: European Institute of Oncology Country: Italy Publications
| Collaborators
|
Detail Information
Publications
Chlorambucil in combination with induction and maintenance rituximab is feasible and active in indolent non-Hodgkin's lymphomaGiovanni Martinelli
European Institute of Oncology, Milan, Italy
Br J Haematol 123:271-7. 2003..Based on our preliminary data, the combination of chlorambucil with rituximab seemed to be well tolerated and active. Its definitive role in the treatment of low-grade NHL should be further evaluated in randomized trials...- Tailored therapy of adult acute leukaemia in Jehovah's Witnesses: unjustified reluctance to treatDaniele Laszlo
Division of Hematology Oncology, Department of Medicine, European Institute of Oncology, Milan, Italy
Eur J Haematol 72:264-7. 2004.... 
Rituximab and subcutaneous 2-chloro-2'-deoxyadenosine as therapy in untreated and relapsed Waldenström's macroglobulinemiaD Laszlo
Department of Haematology, European Institute of Oncology, Milan, Italy
Clin Lymphoma Myeloma Leuk 11:130-2. 2011..024). The combination of rituximab/cladribine is safe and effective in WM patients requiring treatment. The pharmacogenomic analysis suggests that hCNT1 might be beneficial in predicting clinical response to such a combination treatment...- Rituximab and subcutaneous 2-chloro-2'-deoxyadenosine combination treatment for patients with Waldenstrom macroglobulinemia: clinical and biologic results of a phase II multicenter studyDaniele Laszlo
Department of Hematology, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy
J Clin Oncol 28:2233-8. 2010.... - Tissue microarrays in diffuse large B-cell lymphomas: are they really able to identify distinct prognostic groups in lymphomas of both nodal and extranodal origin?D Laszlo
European Institute of Oncology, Milan, Italy
Int J Surg Pathol 19:417-24. 2011..Immunohistochemistry has been proposed as a surrogate for identifying these subgroups, but data about its efficacy in providing prognostic information are conflicting... - Who should be really considered as a poor mobilizer in the plerixafor era?Giovanna Andreola
Stem Cell Collection Unit, European Institute of Oncology, Milan, Italy
Transfus Apher Sci 47:27-32. 2012..0×10(6) CD34+cells/kg required for a successful transplantation. The use of new agent such as CXCR4 antagonist plerixafor might further improve mobilization efficacy in such patients... - Rituximab and subcutaneous cladribine in chronic lymphocytic leukemia for newly diagnosed and relapsed patientsPaola Bertazzoni
Hematoncology Division, European Institute of Oncology, Milan, Italy
Leuk Lymphoma 51:1485-93. 2010..The median time to treatment failure was 37.9 months. Grade 4 neutropenia developed in 5% of patients. The data indicate that combination therapy with rituximab and cladribine is a valuable and safe treatment for patients with CLL... - Clinical activity of rituximab in gastric marginal zone non-Hodgkin's lymphoma resistant to or not eligible for anti-Helicobacter pylori therapyGiovanni Martinelli
European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy
J Clin Oncol 23:1979-83. 2005..The t(11; 18)(q21; q21) translocation seems not to be a predictive marker to response or to subsequent relapse... - The transactivating isoforms of p63 are overexpressed in high-grade follicular lymphomas independent of the occurrence of p63 gene amplificationGiancarlo Pruneri
Division of Pathology and Laboratory Medicine, European Institute of Oncology, Milan, Italy
J Pathol 206:337-45. 2005..Our data suggest that TA-p63 is overexpressed in high-grade FL, possibly independent of the occurrence of gene abnormalities, and that it may be involved in the highly complex mechanism of regulation of apoptosis of FL cells... - Plerixafor and Filgrastim XM02 (Tevagastrim) as a first line peripheral blood stem cell mobilisation strategy in patients with multiple myeloma and lymphoma candidated to autologous bone marrow transplantationGiovanna Andreola
Stem Cell Collection Unit, European Institute of Oncology, Milan, Italy
Eur J Haematol 88:154-8. 2012..0 × 10(6) /kg in a median number of procedures of one. Although preliminary, these data show the combination of biosimilar filgrastim and plerixafor is effective and provides a non-toxic approach to mobilise stem cells... - Cyclin D3 immunoreactivity in follicular lymphoma is independent of the t(6;14)(p21.1;q32.3) translocation or cyclin D3 gene amplification and is correlated with histologic grade and Ki-67 labeling indexGiancarlo Pruneri
Division of Pathology and Laboratory Medicine, European Institute of Oncology, Milan, Italy
Int J Cancer 112:71-7. 2004..Our data suggest that the t(6;14) translocation may be extremely uncommon in FL and that a deregulated expression of cyclin D3, possibly due to epigenetic mechanisms, may be involved in the pathogenesis of high-grade tumors... - Fludarabine combination regimen severely affected peripheral blood stem cell mobilizationDaniele Laszlo
Department of Hematoncology, European Institute of Oncology, Milan, Italy
Acta Haematol 111:228-9. 2004 - Local thrombolytic therapy in cancer patients with central venous catheter occlusion in urgent need of antiblastic treatment: a single institution experienceAlberto Agazzi
Hematoncology Division, European Institute of Oncology, Milan, Italy
J Thromb Thrombolysis 15:109-11. 2003 - Immunoreactivity for cyclin D1 is a reliable marker of gene aberration in plasma cell myeloma but does not specify patients prognosisGiancarlo Pruneri
Leuk Res 32:1628-32. 2008